Brokerages Set Bio-Rad Laboratories, Inc. (NYSE:BIO) Price Target at $333.50

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) have been given an average recommendation of “Hold” by the six research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $333.50.

A number of research analysts have recently commented on the company. Wall Street Zen cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, August 22nd. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bio-Rad Laboratories in a research report on Tuesday, October 14th. Royal Bank Of Canada upped their price target on Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a research report on Friday, August 1st. Wells Fargo & Company upped their price target on Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an “equal weight” rating in a research report on Friday, August 1st. Finally, Zacks Research raised Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 26th.

Bio-Rad Laboratories Stock Up 1.4%

Shares of NYSE:BIO opened at $338.57 on Friday. The company has a market capitalization of $9.16 billion, a PE ratio of 28.86 and a beta of 0.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.12 and a quick ratio of 3.67. The business has a fifty day moving average price of $294.27 and a two-hundred day moving average price of $261.27. Bio-Rad Laboratories has a 1 year low of $211.43 and a 1 year high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, July 31st. The medical research company reported $2.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.93 by $0.68. The firm had revenue of $651.60 million during the quarter, compared to the consensus estimate of $614.82 million. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.11 EPS. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. Analysts forecast that Bio-Rad Laboratories will post 10.81 earnings per share for the current year.

Institutional Trading of Bio-Rad Laboratories

Institutional investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. lifted its holdings in Bio-Rad Laboratories by 0.5% during the 1st quarter. Principal Financial Group Inc. now owns 44,343 shares of the medical research company’s stock worth $10,800,000 after purchasing an additional 236 shares in the last quarter. Crossmark Global Holdings Inc. lifted its holdings in Bio-Rad Laboratories by 14.6% during the 1st quarter. Crossmark Global Holdings Inc. now owns 966 shares of the medical research company’s stock worth $235,000 after purchasing an additional 123 shares in the last quarter. Amundi lifted its holdings in Bio-Rad Laboratories by 16.4% during the 1st quarter. Amundi now owns 23,336 shares of the medical research company’s stock worth $5,478,000 after purchasing an additional 3,294 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Bio-Rad Laboratories during the 1st quarter worth about $816,000. Finally, Acadian Asset Management LLC lifted its holdings in Bio-Rad Laboratories by 79.6% during the 1st quarter. Acadian Asset Management LLC now owns 73,431 shares of the medical research company’s stock worth $17,878,000 after purchasing an additional 32,534 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.